Positive news for Dupixent as pivotal data shows significant improvements in bullous pemphigoid treatment
From GlobeNewswire: 2025-03-08 13:00:00
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD: Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo, along with significant reductions in disease severity and itch. Data supports Dupixent as a potential targeted medicine for bullous pemphigoid, with regulatory submissions under review in the US and the EU. The study enrolled 106 adults with moderate-to-severe BP, with Dupixent-treated patients showing sustained disease remission, reduced corticosteroid use, and lower risk of rescue medication use compared to placebo. The FDA has accepted the supplemental biologics license application for Dupixent to treat BP.
The pivotal ADEPT study evaluated Dupixent in adults with moderate-to-severe bullous pemphigoid, showing positive results in disease remission, disease severity reduction, and itch relief. The study enrolled 106 adults and met primary and key secondary endpoints, demonstrating the potential of Dupixent to be the first targeted medicine for bullous pemphigoid. Dupixent-treated patients achieved significant improvements at 36 weeks compared to placebo, with lower risks of rescue medication use and reduced corticosteroid exposure. Regulatory submissions for Dupixent to treat BP are under review in the US and the EU, with the FDA accepting the supplemental biologics license application.
In elderly patients, Dupixent showed significant improvements in disease remission, disease severity reduction, and itch relief compared to placebo at 36 weeks. The study enrolled 106 adults and met primary and key secondary endpoints, demonstrating the potential of Dupixent to be the first targeted medicine for bullous pemphigoid. Dupixent-treated patients experienced sustained disease remission, reduced corticosteroid use, and lower risk of rescue medication use. Regulatory submissions for Dupixent to treat BP are under review in the US and the EU, with the FDA accepting the supplemental biologics license application.
Read more at GlobeNewswire: Dupixent late-breaking positive pivotal data